PKPD modeling of VEGF, sVEGFR‐2, sVEGFR‐3, and sKIT as predictors of tumor dynamics and overall survival following sunitinib treatment in GIST EK Hansson, MA Amantea, P Westwood, PA Milligan, BE Houk, J French, ... CPT: pharmacometrics & systems pharmacology 2 (11), 1-9, 2013 | 68 | 2013 |
PKPD modeling of predictors for adverse effects and overall survival in sunitinib‐treated patients with GIST EK Hansson, G Ma, MA Amantea, J French, PA Milligan, LE Friberg, ... CPT: pharmacometrics & systems pharmacology 2 (12), 1-9, 2013 | 53 | 2013 |
The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia EK Hansson, LE Friberg Cancer chemotherapy and pharmacology 69, 881-890, 2012 | 37 | 2012 |
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression EK Hansson, JE Wallin, H Lindman, M Sandström, MO Karlsson, ... Cancer chemotherapy and pharmacology 65, 839-848, 2010 | 30 | 2010 |
Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes Y Tomita, E Hansson, F Mazuir, GJ Wellhagen, QX Ooi, E Mezzalana, ... Clinical and translational science 15 (4), 1014-1026, 2022 | 13 | 2022 |
Caplacizumab model‐based dosing recommendations in pediatric patients with acquired thrombotic thrombocytopenic purpura M Bergstrand, E Hansson, B Delaey, F Callewaert, R De Passos Sousa, ... The Journal of Clinical Pharmacology 62 (3), 409-421, 2022 | 12 | 2022 |
Pharmacometric Models for Biomarkers, Side Effects and Efficacy in Anticancer Drug Therapy EK Hansson Acta Universitatis Upsaliensis, 2012 | 6 | 2012 |
PKPD modeling of VEGF, sVEGFR‐2, sVEGFR‐3 and sKIT as biomarkers of tumor response and overall survival following sunitinib treatment in GIST EK Hansson, P Westwood, M Amantea, J French, B Houk, PA Milligan, ... Annual Meeting of the Population Approach Group in Europe (PAGE), 2011 | 3 | 2011 |
Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and … RJ Svensson, QX Ooi, LE Friberg, N Maharaj, PK Reddy, L López‐Lázaro, ... CPT: Pharmacometrics & Systems Pharmacology 12 (2), 154-167, 2023 | 2 | 2023 |
PKPD-modeling of Standard Uptake Value (SUV) in Gastro-Intestinal Stromal Tumors (GIST) patients treated with sunitinib E Schindler, P Westwood, M Amantea, EK Hansson, PA Milligan, ... PAGE Meeting, 2012 | 2 | 2012 |
PS1487 EFFECT OF PLASMA EXCHANGE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF CAPLACIZUMAB L Sargentini, E Hansson, M Bergstrand, F Callewaert, R Sousa HemaSphere 3, 685, 2019 | 1 | 2019 |
PB2249 CAPLACIZUMAB MODEL-BASED DOSING RECOMMENDATIONS IN PEDIATRIC PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA L Sargentini, E Hansson, M Bergstrand, F Callewaert, R Sousa HemaSphere 3 (S1), 1007, 2019 | 1 | 2019 |
The standard treatment protocol is inadequate following overdose of extended release paracetamol: a pharmacokinetic and clinical analysis of 53 cases H Salmonson, G Sjoberg, J Brogren, E Hansson CLINICAL TOXICOLOGY 54 (4), 424-424, 2016 | 1 | 2016 |
Rituximab PK and PKPD evaluation based on a study in diffuse large B-cell lymphoma: influence of tumor size on PK and assessment of PK similarity. RJ Svensson, QX Ooi, LE Friberg, N Maharaj, PK Reddy, L López-Lázaro, ... CPT: Pharmacometrics & Systems Pharmacology, 2022 | | 2022 |
Modelling of Chemotherapy-induced Febrile Neutropenia using the Predicted Degree and Duration of Myelosuppression EK Hansson (1), M. Sandström (2), H. Lindman (3), LE Friberg … E Hansson | | 2007 |